Tesamorelin (Egrifta): GHRH Analogue with FDA Approval
Analysis of Tesamorelin: stabilized GHRH analogue with trans-3-hexenoic acid conjugate, FDA-approved for lipodystrophy in PLHIV. Data from LIPO-010 trials and body composition studies.
Educational Content Only
The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.
Mechanism of Action
Tesamorelin is a 44-amino acid synthetic GHRH analogue conjugated with trans-3-hexenoic acid to increase stability. Studies demonstrate it stimulates pulsatile GH release from the anterior pituitary, elevating IGF-1 and producing documented metabolic effects, especially visceral fat reduction.
Data based on available scientific literature. Protocol individualization depends on qualified professional assessment.
Applications Described in the Literature
- ✓FDA approved (Egrifta) for visceral fat reduction in HIV-associated lipodystrophy
- ✓Body composition studies in adults with GH deficiency
- ✓Research in metabolic fatty liver disease (MAFLD): documented hepatic fat reduction
- ✓Investigations in cognition and dementia: Phase II studies in elderly
- ✓Studies in sarcopenia and body composition in aging
Relevant Studies
Tesamorelin for reduction of excess abdominal fat in HIV-infected patients
2010 · PMID: 20212524
Tesamorelin effects on liver fat and metabolic parameters in HIV-associated lipodystrophy
2012 · PMID: 22090272
Tesamorelin in older adults: effects on GH, IGF-1, and body composition
2015 · PMID: 26248574
Premium
✓ DesbloqueadoProtocols Described in the Literature
Tesamorelin clinical trial protocols (LIPO-010 and LIPO-011) used daily subcutaneous administration. The dose was fixed at 2 mg/day without progressive titration, differentiating it from other GHRH analogues. Studies demonstrate maintained effect over 26 weeks, with sustained response in 52-week extensions.
Dose Ranges Observed in Studies
- ◆FDA-approved dose for HIV lipodystrophy: 2 mg subcutaneous once daily
- ◆Studies in aging/body composition: same 2 mg/day range described in off-label studies
- ◆Duration in efficacy studies: 26–52 weeks with VAT (visceral fat) assessments by DEXA/CT
- ◆Maintenance studies: discontinuation associated with partial visceral fat recovery
Effects Timeline (Literature)
LIPO studies document visceral fat reduction (-15 to -18%) at 26 weeks. IGF-1 elevations detectable in the first 4 weeks. Recovery of ~75% of lost visceral fat documented in 26 weeks after discontinuation. Cognition studies in elderly demonstrated visual memory improvement in 20 weeks.
Documented Associations
- ↗Ipamorelin: plausibility of complementary action to maximize GH response via distinct mechanisms (GHRH vs GHSR)
- ↗CJC-1295: alternative with similar mechanism but much longer half-life (DAC)
- ↗Antiretrovirals: approved use context in HIV lipodystrophy — no significant pharmacological interactions documented
Monitoring Described in Studies
- ⊕Serum IGF-1: assessed every 3 months in study protocols; maintenance within upper normal limit
- ⊕Abdominal visceral fat: single-cut CT scan at L4 or DEXA
- ⊕Fasting blood glucose and HbA1c: monitoring in long-term use studies
- ⊕Anti-tesamorelin antibodies: assessed in immunogenicity studies — low prevalence documented
Clinical Observations from Studies
- ℹOnly FDA-approved GHRH analogue for a specific indication (HIV lipodystrophy)
- ℹNeutralizing antibodies: developed in ~15% of patients, no significant clinical impact documented
- ℹMetabolic effect on hepatic fat: up to 35% reduction documented in MAFLD studies
- ℹCognitive studies (MCI): promising Phase II results, with Phase III studies ongoing
All information above is exclusively educational, based on scientific literature. It does not constitute medical prescription. Individualization of any protocol requires evaluation by a qualified healthcare professional.
Frequently Asked Questions
What is Tesamorelin?▼
Tesamorelin is a synthetic GHRH analogue conjugated to trans-3-hexenoic acid, which stabilizes the molecule against DPP-IV degradation. FDA-approved in 2010 as Egrifta® for reducing visceral fat in HIV-infected adults with lipodystrophy.
⚠️ Medical Disclaimer: The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.